Stannsoporfin FDA Approval Status
FDA Approved: No
Generic name: stannsoporfin
Company: Mallinckrodt Inc.
Treatment for: Hyperbilirubinemia
Stannsoporfin is a heme oxygenase inhibitor in development for the treatment of neonates at risk for developing severe hyperbilirubinemia, or severe jaundice.
Development timeline for stannsoporfin
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.